---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042525"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:06:10.853746+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celularity expects H1 2024 biomaterial revenue >$24M, Rebound >$9M; reaffirms $50-56M FY guidance

## Summary
- Preliminary net revenue from biomaterial products exceeds $24M for six months ended June 30, 2024, surpassing full-year 2023 sales.
- Acquired Rebound allograft matrix from Sequence LifeScience; generated >$9M in net revenue to date, reimbursed via HCPCS Q4296.
- Reaffirms FY 2024 combined net sales guidance of $50-56M for biomaterial and biobanking businesses.
- Plans to file Q2 2024 10-Q in coming weeks; working to regain Nasdaq listing compliance.
- Product pipeline: Celularity Tendon Wrap 510(k) submission expected early 2025, FUSE Bone Void Filler H2 2025, Placental Matrix 2026.

## SEC filing metadata
- accession: 0001493152-24-042525
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315224042525/0001493152-24-042525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315224042525/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042525
- JSON: https://secwatch.observer/filing/0001493152-24-042525.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.